Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks by Mingming Tan, Chenwei Pu, Zhenzhen Wang, Chengwei Jin

Subjects: Get full text

Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer? by Tommaso Porcelli, Cristina Luongo, Anna Cerbone, Carmine Di Luccio, Mariantonia Nacchio, Maria Angela De Stefano, Martin Schlumberger, Domenico Salvatore

Subjects: Get full text

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute... by Xiaoxia Wu, Shenqi Lu, Xinhui Zhang, Zhen Yang, Aining Sun, Depei Wu, Huifen Zhou, Miao Miao

Subjects: Get full text

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors by Russell J. Schilder, Drew Rasco, Manish R. Sharma

Subjects: Get full text

Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study by Chenming Liu, Jintao Chen, Yuxing Liu

Subjects: “…Tyrosine kinase inhibitor…”
Get full text

Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Ad... by Yan-Jei Tang, John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu

Subjects: Get full text

Screening and identification of host signaling pathways for alleviating influenza-induced production of pro-inflammatory cytokines, IP-10, IL-8, and MCP-1, using a U937 cell-based... by Si Chen, Si Chen, Yang Yu, Yue Su, Xiaoqin Lian, Lefang Jiang, Zhuogang Li, Mingxin Zhang, Yarou Gao, Haonan Zhang, Xingjian Zhu, Jiaxin Ke, Xulin Chen

Subjects: Get full text

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials by José Pinto-Fraga, Celia García-Chico, Simone Lista, Pedro Miguel Lacal, Giuseppe Carpenzano, Maurizio Salvati, Alejandro Santos-Lozano, Grazia Graziani, Claudia Ceci

Subjects: Get full text

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy by Anna De Lucia, Lucia Mazzotti, Lucia Mazzotti, Anna Gaimari, Anna Gaimari, Matteo Zurlo, Roberta Maltoni, Claudio Cerchione, Sara Bravaccini, Angelo Delmonte, Lucio Crinò, Patricia Borges de Souza, Luigi Pasini, Fabio Nicolini, Fabrizio Bianchi, Manel Juan, Hugo Calderon, Chiara Magnoni, Chiara Magnoni, Luca Gazzola, Luca Gazzola, Paola Ulivi, Massimiliano Mazza

Subjects: Get full text

Exploring the inhibitory effect and mechanism of isorhamnetin therapy on oral squamous cell carcinoma based on network pharmacology and molecular docking by YU Fangfang, ZHOU Jingjing, YANG Jie, QU Huijuan, HUI Guangyan

Subjects: “…isorhamnetin|oral squamous cell carcinoma|pi3k/akt signaling pathway|src tyrosine kinase|estrogen receptor-1|network pharmacology|molecular docking|experimental verification <i>in vitro</i>…”
Get full text